First-Line Immune-Combination Therapy for Driver Gene-Negative NSCLC With Brain Metastases: Real-World Outcomes.

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.